Saturday, February 23, 2019

Treatment of Clostridium dificile and Related Intestinal Disorders by Fecal Microbiota Transplantation (FMT)


           Within our bodies, there exists a complex system of billions of beneficial microorganisms that is integral to our vitality. Whether it be on our skin or in our intestinal linings, these bacteria perform vital functions that assist in the maintenance of our health. These bacteria are affected by environmental factors, age, genetics, etc., and this is concerning due to the rise in obesity and associated metabolic conditions. These conditions can severely harm ones health and quality of life, and there is controversy surrounding the treatment. Since most of these are caused by deleterious bacteria, aggressive antibiotic treatments have been used to wipe out these pathogens. However, not only do these eliminate the mutualistic bacteria due to the lack of specificity in antibiotics, they also can cause immunity to develop in the harmful strain. This makes further development in antibiotics increasingly difficult, which has lead to research into an alternative form of treatment known as Fecal Microbiota Transplantation.

              Fecal Microbiota Transplantation (FMT) is the transplantation of gut flora between individuals by means of tubes through the anus or mouth to transport the sample to the desired location. This causes direct implantation of bacteria that will cause them to outcompete the negative bacteria in order to alleviate patients of the disease. It was approved by the FDA in the case of Clostridium dificile (C. dificile) infection due to the ineffectiveness of antibiotics. C. dificile is a bacteria that infects the colon and causes severe stomach difficulties. With respect to the efficiency in treatment, FMT proved to be upwards of 90% effective in remediating the symptoms of C. dificile (Marotz, 2016). The efficacy of FMT in C. dificile has led to subsequent research into “superdonors”. These individuals provide a better therapeutic affect and are thought to be either people who live in the same conditions as the patient or contain a keystone bacterial species. Although it is not explicitly clear yet, further research aims at finding what makes these people “superdonors” by testing samples with high concentrations of different strains of gut flora. Although there are many positive aspects to this type of treatment, there are several drawbacks. Besides the obvious social stigma and concerns, many test subjects are very ill so it is very hard to tell whether the FMT brought about even more illness due to the transfer of bacteria. Also, there is extreme varying in success, and the difference between a 90+% and 20% effectiveness can be the difference between the technique being approved for further treatment or not. Finally, there may be other unintended systemic affects, however, these may be outweighed by the benefits of the FMT procedure.
-Ethan Subel

LINK TO PAPER: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045147/

Marotz, Clarisse, Zarrinpar, Amir. 2016. “Treating Obesity and                            Metabolic Syndrome with Fecal Microbiota Transplantation”.                        Yale Journal of Biology and Medicine, 89: 383-388.

No comments: